Alamar is designed to enable the earliest possible detection of disease through ultra-sensitive protein analysis.
This next-generation proteomics service identifies low-abundance proteins that are often below the detection limits of conventional technologies, enabling earlier biological insight and improved biomarker discovery.
We offer advanced biomarker analysis services using Alamar Biosciences’ NULISA™ platform, powered by the ARGO® HT System. This innovative technology delivers ultra-sensitive, multiplexed protein profiling from minimal sample volumes, making it ideally suited for plasma and other biofluids.
Contact us and one of our experienced account managers will arrange a complimentary consultation, including detailed information, workflow guidance, and transparent pricing options.
Certified Provider of Alamar Biosciences High-Sensitivity Proteomics
As an Alamar Biosciences certified provider, we are formally accredited to deliver high-sensitivity proteomic analysis using the Alamar Biosciences platform, ensuring validated workflows, technical proficiency, and data quality aligned with the manufacturer’s standards.
What Is Alamar Biosciences Proteomics?
Alamar Biosciences’ mission is to enable early detection of disease through automated, high-sensitivity protein analysis across a wide range of multiplex levels, supporting the translation of critical biomarkers from discovery through to clinical research.
Key advantages include:
- Unparalleled sensitivity at low ag/mL levels, enabling detection of low-abundance biomarkers in complex matrices such as serum, plasma, and CSF.
- Exceptional flexibility, supporting single-plex assays through to panels of tens to thousands of proteins, spanning up to 12 logs of dynamic range using the same robust chemistry.
- High reproducibility, with <10% CV, ensuring reliable and consistent results across studies.
- Fully automated workflows, with less than 30 minutes of hands-on time, allowing easy implementation across a range of laboratory environments.
Quantitative and Qualitative Protein Analysis
Advanced biomarker analysis services using Alamar Bioscience’s NULISA™ platform, which combine proprietary sequential immunocomplex capture and release with next-generation sequencing (NGS). This approach delivers attomolar sensitivity alongside scalable multiplexing.
The result is reliable detection of ultra-low-abundance biomarkers that are often undetectable using traditional immunoassays or mass spectrometry-based approaches.
Minimal sample input requirements make this platform ideal for precious or limited biofluid samples.
Why Choose Alamar Biosciences for Proteomics?
Unlike traditional mass spectrometry approaches, Alamar’s NULISA™ technology delivers highly sensitive protein quantification without complex sample preparation or lengthy analytical workflows.
Capabilities and Performance
Available panels include:
Supporting Clinical and Translational Proteomics
Alamar Biosciences is ideally suited for scientists and organisations working in:
- Early disease detection
- Biomarker discovery and validation
- Inflammation and cancer research
- Neurodegenerative disease research (including Alzheimer’s and dementia)
- Pre-clinical mouse model studies
- Pharmaceutical and biotech research
Source Genomics supports proteomics research across a range of therapeutic areas, including:
- Cardiometabolic disease
- Oncology
- Neurology
- Inflammation and immune-mediated disorders
- Neurodegeneration
These applications enable biomarker discovery for disease prediction, drug target identification, patient stratification, and treatment response monitoring.
Accelerate your proteomics research with Alamar® Proteomics on the ARGO™ HT System. Contact our team today to discuss assay selection, study design, and sample requirements.